Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.45 |
| ▸ | GABRD | O14764 | 4/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.45 |
| ▸ | GABRE | P78334 | 4/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366721 | 0.86 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2927788 | 0.81 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2655336 | 0.81 | CES2 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10487686 | 0.80 | CASP7 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10983387 | 0.80 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1706655 | 0.80 | KEAP1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6700773 | 0.80 | ALB (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28417296 | 0.79 | CES2 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5830747 | 0.79 | GABRP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4879411 | 0.79 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910298-B1 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | GABRP 2338/4885GABRD 4661/4885GABRA1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.